Single-component bismuth nanoparticles as a theranostic agent for multimodal imaging-guided glioma therapy

Publication date: Available online 13 April 2019Source: Computational and Structural Biotechnology JournalAuthor(s): Shu-Ting Lu, Dan Xu, Ru-Fang Liao, Jia-Zhen Luo, Yu-Hang Liu, Zhen-Hua Qi, Cai-Ju Zhang, Nai-Li Ye, Bo Wu, Hai-Bo XuAbstractSingle-component nanomaterials such as bismuth (Bi) based on nanoparticles (NPs) intrinsically having both diagnostic and therapeutic capabilities are widely needed in biomedical fields. However, their design and fabrication still face enormous challenges. Here, a kind of pure Bi NPs with ultrahigh X-ray attenuation coeffcient was developed and evaluated as a simple but powerful theranostic nanomaterals and potent light-to-heat conversion efficiency for photoacuostic imaging (PAI)/photothermal therapy (PTT) in this study. The prepared pure Bi NPs showed excellent photothermal performance and the temperature of NPs solution (1 mg/mL) increased to 70 °C under near-infrared light irradiation within 4 min. The pure Bi NPs showed obvious enhancement effect both in X-ray computed tomography (CT) and PA imaging modalities in vivo. In addition, the glioma growth was efficiently suppressed by the pure Bi NPs after 808 nm laser irradiation, while maintained the biosafety and low toxicity. Thus, it is notable that this type of Bi nanomaterial has great potential in multi-imaging guided cancer treatment.Graphical Abstract
Source: Computational and Structural Biotechnology Journal - Category: Biotechnology Source Type: research

Related Links:

Positron emission tomography (PET) and PET/computed tomography (PET/CT) imaging with 3,4-dihydroxy-6-[18F] fluoro-L-phenylalanine (18F-FDOPA) has been used in the evaluation of gliomas. We performed a meta-analys...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Background: In the past decade, positron emission tomography/computed tomography (PET/CT) has become an important imaging tool for clinical assessment of tumor patients. Our meta-analysis aimed to compare the predictive value of PET/CT parameters regard to overall survival (OS) and progression-free survival (PFS) outcomes in glioma.Methods: Relevant articles were systematically searched in PMC, PubMed, EMBASE and WEB of science. Studies involving the prognostic roles of PET/CT parameters with OS and PFS in glioma patients were evaluated. The impact of metabolic tumor volume (MTV), maximal standard uptake value (SUVmax), an...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
The clinical phenomenon of a spontaneous disappearance of an enhancing lesion on cerebral computed tomography (CCT) or magnetic resonance imaging with gadolinium (MRI) is referred to as a vanishing tumor [1]. This is a phenomenon observed in 1:60.000 –1:100.000 cancer patients. [2] The differential diagnoses include primary central nervous system lymphoma (PCNSL), demyelinating disease, glioma with spontaneous regression, inflammatory disease, such as sarcoidosis, Behcets disease/angiitis with granoulomatosis and parasitic disease.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Conclusion Astroblastoma is an extremely rare CNS tumor. Morphological diagnosis is difficult, as the typical astroblastic rosettes may be present also in other CNS tumors, including some gliomas and ependymomas. In fact, AB can be considered as a morphologic pattern, which can be associated with a spectrum of molecular entities. Total resection is the best treatment; the precise role of chemotherapy and radiotherapy is still debated, particularly for high-grade tumors. We believe that DNA-methylation profiles represents an important instrument for confirming diagnosis, predicting prognosis and better defining the molec...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusions Several model systems are now available to characterize the MSC-tumour interplay in the TME. These offer early promise in establishing robust preclinical platforms for the identification of crucial molecular pathways and for the assessment of clinical efficacy of novel drugs to inhibit cancer development and progression. However, selection of the right model for a given study should be shaped on the purpose, and should also consider fixed biological, biochemical, and biophysical parameters according to the specific tumour type. Finally, in order to get reliable and useful results to be translated to the clinic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Gui-Jiang Wei1,2, Ming-Qing Yuan1, Li-He Jiang1, Yu-Lan Lu3, Chun-Hong Liu3, Hong-Cheng Luo3, Hua-Tuo Huang3, Zong-Quan Qi1* and Ye-Sheng Wei1,2* 1Department of Cell Biology, Medical College of Guangxi University, Nanning, China 2Department of Medical Laboratory, Affiliated Hospital of Guilin Medical University, Guilin, China 3Department of Medical Laboratory, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China miRNAs are small non-coding RNAs modulating gene expression, and variants in miRNA genes are involved in the pathogenesis of ischemic stroke (IS). However, the effect of mi...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conclusion: The efficacy of brainstem gliomas—treated with CyberKnife is efficacious with mild toxicity. Introduction Brainstem gliomas (BSGs) account for 5–15% of brain tumors and more likely happen in children (1). BSGs constitute at least 20% of childhood brain neoplasms (2), and the peak age is 7–9 years. In contrast, BSGs is rare in the adult population and account for only 1.5–2.5% of brain glioma, with a peak age of 40–70 years (1). Diffuse intrinsic pontine glioma(DIPG) was the most common type of BSG is that could invade the whole brainstem including midbrain, pons as well as me...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study had a retrospective multicenter (two hospitals in China) design and a radiomic analysis was performed using contrast enhanced CT in advanced HGSOC (FIGO stage III or IV) patients. We used a minimum 18-month follow-up period for all patients (median 38.8 months, range 18.8–81.8 months). All patients were divided into three cohorts according to the timing of their surgery and hospital stay: training cohort (TC) and internal validation cohort (IVC) were from one hospital, and independent external validation cohort (IEVC) was from another hospital. A total of 620 3-D radiomic features were extracted and a Lass...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThere was no difference in the pattern of [18F]FDG accumulation with time in MDA-MB-231 tumors and inflammatory lesions. We found that [18F]FDG efflux accelerated in activated macrophages reflecting increased G6Pase expression after activation and lower expression of HK II protein than that in MDA-MB-231 cancer cells.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Biotechnology | Brain Tumor | Cancer | Cancer & Oncology | CT Scan | Glioma | Nanotechnology | Study | Toxicology